Benlysta

DRUG3 trials

Sponsors

GlaxoSmithKline, Janssen Research & Development, LLC

Conditions

HealthySystemic Lupus Erythematosus

Phase 1

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2

CompletedNCT04611971

Janssen Research & Development, LLCHealthy

Start: 2020-10-27End: 2021-05-06Updated: 2025-02-03

Unknown Phase

Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry

CompletedNCT01729455

GlaxoSmithKlineSystemic Lupus Erythematosus

Start: 2013-02-21End: 2025-02-28Updated: 2026-03-20

BENLYSTA® Special Drug Use Investigation

CompletedNCT03370263

GlaxoSmithKlineSystemic Lupus Erythematosus

Start: 2018-01-15End: 2025-09-26Updated: 2026-01-27

Related Papers

MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT

Lupus Science & Medicine2022-09-011 citations

A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus

Lupus2017-05-0345 citations